Ratings Immatics N.V.

Equities

IMTX

NL0015285941

Real-time Estimate Cboe BZX Other stock markets 11:02:15 2024-05-20 am EDT			5-day change	1st Jan Change
10.74 ^USD	-1.96%		-2.27%	+2.09%

May. 15	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
May. 14	Immatics' Q1 Loss Narrows. Revenue Rises	MT

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
IMMATICS N.V.	+2.09%	1.13B	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.78%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+11.91%	106B	B+
ARGENX SE	-2.74%	21.96B	B
BIONTECH SE	-13.96%	21.87B	B+
GENMAB A/S	-5.29%	19.21B	A-
BEIGENE, LTD.	-3.02%	18.08B	B
WUXI APPTEC CO., LTD.	-38.57%	17.71B	A-
NEUROCRINE BIOSCIENCES, INC.	+6.41%	14.32B	C+
SAREPTA THERAPEUTICS, INC.	+35.11%	12.42B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes